Please login to create your UC TechAlerts.
Request a new password for
No technologies match these criteria. Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above
Find technologies available for licensing from UCLA.
PIAS Proteins and Its Monoclonal Antibody as Diagnostics and Therapeutics for Immunological Disorders and Cancer
Brief description not available
Redox Responsive Polymeric Nanocapsules for Protein Delivery
Researchers at UCLA have developed novel nanocapsules that preferentially direct protein delivery to the intracellular space of cells. The invention overcomes the major challenge of stability for protein-based therapeutics.
Diagnostic Biomarkers for the Early Detection of Woman's Cancer, Including Ovarian, Uterine and Colon
Researchers at UCLA's Jonsson Comprehensive Cancer Center have identified a naturally occurring human protein, apolipoprotein (ApoA-I), which helps kill ovarian cancer cells and improves overall survival. Experimental data suggest that apoA-I and apoA-I mimetic peptides are promising therapeutic agents for the treatment of human ovarian cancer. The powerful anti-cancer effect of apoA-I is demonstrated with strong inhibition of tumor growth and spreading in animal models of ovarian cancer.
Modification of Peptides Using bis(thioether) ArylBridge (tABTM) Approach
Researchers in UCLA’s Department of Medicine have developed a novel peptide bridging technology that is a more efficient and cost-effective alternative to stapling technology for the manufacturing of peptide therapeutics.
Inhibitors Of The N-Terminal Domain Of The Androgen Receptor
UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.
Novel Small Molecules that Target Cancer Stem Cells for the Treatment of Cancer
Second-Generation Estrogen Receptor Down-Regulators for Medical Therapy
UCLA researchers in the School of Medicine have developed a series of novel estrogen receptor antagonists for breast cancer therapy.
Azuvirins: Novel Peptides with Antiviral and Antineoplastic Potential
UCLA researchers have designed and produced a series of small peptides that demonstrate outstanding synergistic efficacy with radiation in treating tumor growth and development. In addition, the peptides are potent inhibitors of viral infection from HIV and herpes simplex virus (HSV).
A Digital Microfluidic Chip for Automated Analysis of Protein Structure
UCLA scientists have developed an automated microfluidic platform that uses on-chip hydrogen-deuterium exchange (HDX) coupled with mass spectrometry (MS) to characterize protein structure.
Anti-Cspg4 Fusions with Type I Interferon for the Treatment of Malignancy
UCLA researchers have developed antibody-interferon fusion proteins that show high efficacy against cancer cells in vitro and in vivo.
New Compounds For The Treatment Of Diseases Related To Protein Misfolding
UCLA researchers in the Department of Neurology with an international team of scientists have developed compounds for therapeutic use in protein misfolding diseases.
Hyperbranched Polyglycerol Encapsulated Proteins for Oral Protein Delivery
Novel Antiviral Compounds to Treat Enterovirus Infections
Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.
Broad-spectrum Antimicrobial Peptide for the Treatment of Acne and Skin Cancer
Vectors for Antibody Expression
Use of a Gene and Related Mouse Model for the Study and Development of Therapeutics for Neuropsychiatric Disorders
Granulin as a Target for Tumor Diagnosis and Growth Regulation
Small Molecules to Facilitate Therapeutic Exon Skipping
Investigators at UCLA have discovered a series of small molecules to facilitate therapeutic exon skipping. The use of these identified molecules may enhance the effectiveness of antisense oligonucleotide agents currently in clinical development.
Netrin-1 Compounds as Post-MI and Post-Angioplasty Therapeutics as well as for Treating Renal and CNS Reperfusion Injury
UCLA researchers have invented a method of decreasing myocardial injury and infarct size through the intravenous administration of the netrin-1 or netrin-1-derived peptides during a cardiac event. These agents have powerful cardioprotective effects and provide a novel and effective therapy for the treatment of myocardial infarction.
MicroRNA-Targeting Therapeutics for IBD and Colon Cancer
Dr. Dimitrios Iliopoulos in UCLA Department of Medicine has identified a novel biomarker, microRNA-214 (miR-214), that predicts, at near 100% specificity, an ulcerative colitis patient’s risk for developing colon cancer.
Novel Gene Therapy for Aids Using Mutated tRNA
Antibody Therapy for Inhibiting Bladder Cancer and Prostate Cancer Metastasis
UCLA has a robust intellectual property position on antibody-based diagnostics and therapeutics against N-cadherin for the treatment and detection of prostate and bladder cancers. The research and development leading to this promising technology has been conducted by Dr. Robert Reiter, Professor of Urology and Director of UCLA’s Prostate Cancer Program.
Small Molecule Inhibitors of Cardiovascular and Renal Ectopic Calcification
UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.
An Amplified and Overexpressed Gene in Colorectal Cancers
Novel Anti-TfR Antibodies For Improved Cancer Treatment
Dr. Manuel Penichet and colleagues at the UCLA Departments of Surgery and Microbiology, Immunology, and Molecular Genetics have developed a novel anti-human transferrin receptor (TfR) antibody for the treatment of incurable hematological malignancies such as multiple myeloma and aggressive lymphoma.
Gateway to Innovation, Research and Entrepreneurship